22 material Form 8-K filings that 21 companies we cover made with the SEC in August 2023, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
QuinStreet reported fiscal fourth-quarter 2023 revenue of $130.3 million, down 11% from a year earlier, and a GAAP net loss of $55.9 million, or $1.03 per diluted share, which includes a $51.9 million tax valuation allowance. Adjusted EBITDA was $1.8 million, versus $5.1 million a year earlier, and the company guided fiscal first-quarter 2024 revenue to $120 million to $125 million.
Q4 revenue $130.3 million, down 11% year over year; full fiscal 2023 revenue $580.6 million, approximately flat
GAAP net loss $55.9 million ($1.03 per diluted share) in Q4 and $68.9 million for fiscal 2023; the Q4 result includes a $51.9 million tax valuation allowance
Adjusted EBITDA $1.8 million in Q4 and $16.7 million for fiscal 2023
Company expects fiscal 2024 revenue and adjusted EBITDA to grow at double-digit rates; fiscal Q1 revenue guidance is $120 million to $125 million, with adjusted EBITDA approximately break-even
Krystal Biotech reported a second-quarter 2023 net loss of $33.2 million, or $(1.25) per share, up from $28.1 million, or $(1.10) per share, a year earlier. The filing reports no revenue figure; it cites 121 Patient Start Forms for VYJUVEK in the first six weeks after its May 19 FDA approval, and $505.9 million in cash, cash equivalents and investments at June 30, 2023.
Q2 2023 net loss was $33.2 million, or $(1.25) per share, versus $28.1 million, or $(1.10) per share, in Q2 2022.
General and administrative expenses rose to $25.9 million from $17.9 million, and R&D expenses rose to $12.1 million from $10.9 million.
As of June 30, the company had received 121 VYJUVEK Patient Start Forms, 30 of them for dominant dystrophic epidermolysis bullosa.
Cash, cash equivalents and investments totaled $505.9 million on June 30, 2023.
New York Mortgage Trust, Inc. (Nasdaq: NYMT) reported a second-quarter 2023 net loss attributable to common stockholders of $37.2 million, or $0.41 per share, compared with a net loss of $82.4 million, or $0.86 per share, a year earlier, and net income of $10.5 million in the first quarter of 2023. Book value per common share fell to $12.44 from $12.95 at March 31, 2023, and the common dividend was $0.30, down from $0.40 in prior quarters. The filing header lists Adamas Trust, Inc. (ADAM), but the attached press release and financial tables are for New York Mortgage Trust.
Net loss attributable to common stockholders was $37.2 million, or $0.41 per share, for the quarter ended June 30, 2023, versus $82.4 million, or $0.86 per share, for the same quarter of 2022
Total net interest income was $15.1 million, down from $39.3 million a year earlier and $17.8 million in the first quarter of 2023
Book value per common share was $12.44 at June 30, 2023, compared with $12.95 at March 31, 2023
Dividends declared per common share were $0.30, compared with $0.40 in each of the prior four quarters
Connection (PC Connection, Inc.) reported second-quarter 2023 net sales of $733.5 million, down 11.5% from a year earlier, and net income of $19.7 million, or $0.75 per diluted share, down 22.4% from $0.96. The company said gross margin rose 90 basis points to 17.4%, and its board declared a quarterly dividend of $0.08 per share.
Net sales were $733.5 million, down 11.5% year over year; gross profit was $127.8 million, down 6.7%.
Diluted EPS was $0.75 versus $0.96 a year earlier; adjusted diluted EPS was $0.80 versus $0.96.
Quarterly dividend of $0.08 per share is payable September 1, 2023, to shareholders of record as of August 15, 2023.
Cash and cash equivalents were $244.0 million at June 30, 2023, versus $94.9 million a year earlier.
Xenia Hotels & Resorts reported second quarter 2023 results on August 2, 2023. Net income attributable to common stockholders fell 50.1% to $13.8 million, Adjusted EBITDAre fell 15.7% to $74.7 million, and Adjusted FFO per diluted share fell to $0.47 from $0.57 a year earlier. The company updated full-year 2023 guidance, raising the low end of several ranges while lowering the high end of most measures, which shows the weaker second quarter is affecting the outlook.
Q2 2023 net income attributable to common stockholders was $13.8 million, or $0.12 per share, down from $27.6 million, or $0.24 per share, in Q2 2022
Adjusted EBITDAre was $74.7 million, down 15.7%; Same-Property RevPAR was $182.49, down 2.0%
Full-year 2023 Same-Property RevPAR change guidance is 4% to 6%, with the high end lowered by 2 percentage points; Adjusted FFO per diluted share guidance is $1.42 to $1.60
In Q2 the company repurchased 2,539,888 shares for approximately $31.9 million and retired $30 million of 6.375% Senior Notes due August 2025
Watsco reported second-quarter 2023 results on August 1, 2023, with sales down 6% to $2.0 billion and diluted EPS down 10% to $4.42 from $4.93. The company attributed part of the decline to a product transition under new efficiency regulations and to OEM production and availability delays, which it estimated reduced quarterly sales by $75 to $80 million. For the six months, sales fell 3% to $3.55 billion and EPS fell 7% to $7.25.
Second-quarter sales of $2.0 billion, down 6%; operating income of $266 million, down 7%
Second-quarter diluted EPS of $4.42, versus $4.93 a year earlier
Company estimated OEM-related delays reduced quarterly sales by $75 to $80 million ($115 to $125 million for six months)
Operating cash flow was a $89 million use of cash for the six months ended June 30, 2023; annual dividend rate is $9.80 per share
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.